Edwards Lifesciences Corporation $EW Shares Sold by Alyeska Investment Group L.P.

Key Points

• Alyeska Investment Group cut its Edwards Lifesciences stake by 26.5% in the second quarter, selling 293,476 shares and retaining 812,860 shares worth approximately $73.5 million.
• Institutional investors and hedge funds own 79.46% of Edwards Lifesciences, while several major firms—including BlackRock and Bank of New York Mellon—established or increased positions.
• Edwards reported quarterly revenue of $1.74 billion and EPS of $0.78, exceeding analyst expectations; analysts maintain a “Moderate Buy” consensus with an average price target of $100.27.

Alyeska Investment Group L.P. trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 26.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 812,860 shares of the medical research company's stock after selling 293,476 shares during the period. Alyeska Investment Group L.P. owned 0.14% of Edwards Lifesciences worth $73,531,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. purchased a new stake in shares of Edwards Lifesciences during the second quarter worth approximately $5,318,092,000. State Street Corp lifted its stake in shares of Edwards Lifesciences by 1.5% in the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company's stock worth $2,215,777,000 after buying an additional 371,892 shares in the last quarter. Wellington Management Group LLP boosted its position in Edwards Lifesciences by 4.8% during the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company's stock worth $1,857,934,000 after acquiring an additional 989,533 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Edwards Lifesciences during the second quarter worth about $1,274,082,000. Finally, Norges Bank purchased a new stake in Edwards Lifesciences during the 4th quarter valued at about $803,686,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Activity

In related news, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Bruls sold 2,644 shares of the company's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares of the company's stock, valued at $1,618,200.32. This trade represents a 12.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 4,501 shares of company stock worth $408,213 in the last three months. Corporate insiders own 0.31% of the company's stock.

Edwards Lifesciences Stock Up 0.3%

Shares of Edwards Lifesciences stock opened at $90.19 on Friday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a market capitalization of $51.93 billion, a P/E ratio of 51.83, a P/E/G ratio of 2.37 and a beta of 0.85. The company has a 50 day moving average of $89.54 and a 200 day moving average of $85.03.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the prior year, the firm posted $0.67 EPS. The company's quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on EW. Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Saturday, July 4th. TD Cowen reiterated a "buy" rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. BTIG Research raised their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. Citigroup lifted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and a consensus price target of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source